AMRX
Price
$8.42
Change
+$0.05 (+0.60%)
Updated
Jul 3 closing price
Capitalization
1.87B
32 days until earnings call
EBS
Price
$6.99
Change
-$0.12 (-1.69%)
Updated
Jul 3 closing price
Capitalization
120.07M
37 days until earnings call
Interact to see
Advertisement

AMRX vs EBS

Header iconAMRX vs EBS Comparison
Open Charts AMRX vs EBSBanner chart's image
Amneal Pharmaceuticals
Price$8.42
Change+$0.05 (+0.60%)
Volume$898.79K
Capitalization1.87B
Emergent Biosolutions
Price$6.99
Change-$0.12 (-1.69%)
Volume$917.38K
Capitalization120.07M
AMRX vs EBS Comparison Chart in %
Loading...
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AMRX vs. EBS commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a Buy and EBS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (AMRX: $8.42 vs. EBS: $6.99)
Brand notoriety: AMRX and EBS are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: AMRX: 47% vs. EBS: 72%
Market capitalization -- AMRX: $1.87B vs. EBS: $120.07M
AMRX [@Pharmaceuticals: Other] is valued at $1.87B. EBS’s [@Pharmaceuticals: Other] market capitalization is $120.07M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileEBS’s FA Score has 1 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • EBS’s FA Score: 1 green, 4 red.
According to our system of comparison, both AMRX and EBS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 6 TA indicator(s) are bullish while EBS’s TA Score has 4 bullish TA indicator(s).

  • AMRX’s TA Score: 6 bullish, 3 bearish.
  • EBS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, AMRX is a better buy in the short-term than EBS.

Price Growth

AMRX (@Pharmaceuticals: Other) experienced а +3.57% price change this week, while EBS (@Pharmaceuticals: Other) price change was +2.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.02%. For the same industry, the average monthly price growth was +2.94%, and the average quarterly price growth was +92.60%.

Reported Earning Dates

AMRX is expected to report earnings on Aug 07, 2025.

EBS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.02% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMRX($1.87B) has a higher market cap than EBS($120M). AMRX has higher P/E ratio than EBS: AMRX (90.00) vs EBS (17.73). AMRX YTD gains are higher at: 6.313 vs. EBS (-26.883). AMRX has higher annual earnings (EBITDA): 400M vs. EBS (-518.2M). EBS has more cash in the bank: 112M vs. AMRX (91.5M). EBS has less debt than AMRX: EBS (860M) vs AMRX (2.75B). AMRX has higher revenues than EBS: AMRX (2.39B) vs EBS (1.02B).
AMRXEBSAMRX / EBS
Capitalization1.87B120M1,558%
EBITDA400M-518.2M-77%
Gain YTD6.313-26.883-23%
P/E Ratio90.0017.73508%
Revenue2.39B1.02B234%
Total Cash91.5M112M82%
Total Debt2.75B860M320%
FUNDAMENTALS RATINGS
AMRX vs EBS: Fundamental Ratings
AMRX
EBS
OUTLOOK RATING
1..100
247
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
58100
SMR RATING
1..100
9994
PRICE GROWTH RATING
1..100
4648
P/E GROWTH RATING
1..100
2811
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EBS's Valuation (57) in the Biotechnology industry is somewhat better than the same rating for AMRX (90) in the Pharmaceuticals Major industry. This means that EBS’s stock grew somewhat faster than AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (58) in the Pharmaceuticals Major industry is somewhat better than the same rating for EBS (100) in the Biotechnology industry. This means that AMRX’s stock grew somewhat faster than EBS’s over the last 12 months.

EBS's SMR Rating (94) in the Biotechnology industry is in the same range as AMRX (99) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as EBS (48) in the Biotechnology industry. This means that AMRX’s stock grew similarly to EBS’s over the last 12 months.

EBS's P/E Growth Rating (11) in the Biotechnology industry is in the same range as AMRX (28) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to AMRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXEBS
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
68%
MACD
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 4 days ago
76%
Declines
ODDS (%)
N/A
Bearish Trend 19 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
73%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 6 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EMACX13.950.06
+0.43%
Gabelli Entpr Mergers & Acquisitions C
NAWGX50.690.19
+0.38%
Voya Global High Dividend Low Vol A
WFMDX48.820.11
+0.23%
Allspring Special Mid Cap Value Admin
FBOGX9.820.02
+0.20%
Templeton Global Smaller Comp R6
MGLLX16.690.02
+0.12%
MFS Global Real Estate R3

AMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with PAHC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then PAHC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
+0.60%
PAHC - AMRX
47%
Loosely correlated
+0.21%
VTRS - AMRX
42%
Loosely correlated
-0.21%
EBS - AMRX
40%
Loosely correlated
-1.69%
AMPH - AMRX
40%
Loosely correlated
-1.61%
ZTS - AMRX
39%
Loosely correlated
+0.06%
More

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with AMRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-1.69%
AMRX - EBS
40%
Loosely correlated
+0.60%
HROW - EBS
40%
Loosely correlated
+3.86%
HKMPF - EBS
34%
Loosely correlated
N/A
SIGA - EBS
34%
Loosely correlated
N/A
VTRS - EBS
33%
Poorly correlated
-0.21%
More